Creo Medical Group PLC Creo founder in Sunday Times 100 UK entrepreneurs
18 March 2019 - 6:01PM
RNS Non-Regulatory
TIDMCREO
Creo Medical Group PLC
18 March 2019
Creo Medical Group plc
("Creo" or the "Company")
Creo founder named in Sunday Times list of top 100 UK
entrepreneurs
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
Chris Hancock, founder of Creo and Chief Technology Officer, was
named in the Sunday Times Maserati 100, its annual list of
inspiring entrepreneurs.
The 2019 Maserati 100 is the fifth annual celebration of UK
entrepreneurial excellence and this year's theme was 'innovators'
recognising entrepreneurs who have contributed original thinking to
their industry, in particular those who have had a big idea and
converted it into a business success. Nominations were judged by a
panel of industry experts from the Sunday Times and the list was
published in the Sunday Times Business section over the
weekend.
Details of the 2019 Maserati 100 can be seen here:
https://www.thetimes.co.uk/edition/business/maserati-top-100-meet-the-innovators-bp353zlvr
About Chris Hancock
Chris has over 20 years of experience in medical device
development including four years at Gyrus Group plc in his role as
Senior Engineer. Chris holds a personal Chair in the Medical
Microwave Systems Research Group at Bangor University. Chris is a
Fellow of the Institute of Physics, a Chartered Physicist, Fellow
of the Institute of Engineering and Technology, a Chartered
Engineer and a Senior Member of the IEEE. He is a named inventor
and lead author on over 500 patents/patent applications and journal
publications.
Chris Hancock, Chief Technology Officer and Founder of Creo
Medical, said: "I am both delighted and humbled to have been
included within a list of some extraordinary entrepreneurs and
innovators from the UK. I am so pleased with the progress that
we've made since I started the business with little more than two
people, a garage to work from, and a vision to create a platform to
apply microwave and RF energy to surgical endoscopy and deliver
real-life improvements to cancer patients.
"We are moving ever closer to the full commercial launch of our
suite of products initially focussed on gastrointestinal
therapeutic endoscopy, and I am very excited by the continued drive
for innovation that the business maintains. I look forward to
continuing to expand our suite of products focussed on
gastrointestinal cancer, and to the ongoing development of our soft
tissue ablation range of devices, which could have game changing
implications for pancreatic and lung cancer treatment and other
indications."
Creo Medical Group plc
Richard Rees (CFO) +44 (0)129 160 6005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys / Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Helen Cresswell Mob: +44 (0)7841 917 679
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical advanced energy platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing a safer, less-invasive and more
cost-efficient option of treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADMGMFRNVGLZM
(END) Dow Jones Newswires
March 18, 2019 03:01 ET (07:01 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024